KYMR Stock — Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. (KYMR)

Updated October 16, 2026.

KYMR is a Stock. Total return is 215.0% over the past 6.2 years, 70.3 points ahead of SPY at 144.7%.

Kymera Therapeutics is a clinical-stage biopharmaceutical company developing small molecule drugs designed to degrade disease-causing proteins, with lead candidates in clinical trials for conditions including atopic dermatitis, asthma, autoimmune diseases, and oncology indications; the company has a strategic partnership with Sanofi for development of certain drug candidates. As an early-stage biotech company, it does not currently distribute to shareholders. This security appeals to investors seeking exposure to clinical-stage biopharmaceutical development with a longer-term, higher-risk profile.

KYMR performance versus SPY

Price and return data through 2026-10-16.

Total return is 215.0% over the past 6.2 years, 70.3 points ahead of SPY at 144.7%. Over the past year its total return — price change plus distributions reinvested — is 73.3%. Its deepest 1-year drawdown was 27.7%.

KYMR key facts

Asset type

Stock

Asset class

Equity

Inception date

08/21/2020

Distribution frequency

None

Last close

$104.78 (as of 2026-10-16)

Market cap

$8,712,521,754

Average volume

488723.0

Beta

1.984

Payout ratio

0.0%

EPS

$-3.25

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

KYMR risks and drawbacks

The deepest 1-year drawdown on record here is 27.7%.

Who may consider KYMR — and who may not

It is a weaker fit for investors who need monthly cash flow (KYMR does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on KYMR

• All tickers starting with K

Tagged: Healthcare.

Frequently asked questions